A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma.
Paula RestrepoSherry BhallaYogita Ghodke-PuranikAdolfo AlemanVioletta V LeshchenkoDavid T MelnekoffSarita AgteJoy J JiangDeepu MadduriJoshua RichterShambavi RichardAjai ChariHearn Jay ChoSundar JagannathChristopher J WalkerYosef LandesmanAlessandro LaganàSamir S ParekhPublished in: JCO precision oncology (2022)
In this study, we present a present a novel, three-gene expression signature that predicts selinexor response in MM. This signature has important clinical relevance as it could identify patients with cancer who are most likely to benefit from treatment with selinexor-based therapy.